These above results indicated that combining the clinical characteristics of DLBCL with the expression of TRIB3 could predict the prognosis of patients with DLBCL in 1-, 3-, and 5-year intervals, which was expected to provide a more effective reference for clinicians and formulate effective intervention measures. Here, TRIB3 is linked to diffuse large B-cell lymphoma.